After having established a strong presence in formulations and APIs, the Ahmedabad─ based Cadila Healthcare, popularly known as Zydus Cadila, 4th largest player in the Indian pharmaceutical market, is betting big on biosimilars
Original Article: Zydus Cadila eyes US$ 200 mn revenue from biosimilar segment by 2021